A new type of herbal medicine, dubbed baisens herbal medicinal, can be purchased in India and it is a miracle for people with chronic pain and cancer, according to an article published by the Indian Medical Association (IMA).
The article by Dr. Shishir Singh, of the Royal Institute of Medical Sciences in Bangalore, describes how the baisen medicine works.
“It is a new drug developed by the pharmaceutical industry, and it has a very unique property.
The baisenes has been found to reduce the pain and swelling caused by cancer, and also help to reduce inflammation,” he said.
Singh was also the first author of the first report in the journal of the Indian Council of Medical Research (ICMR) on baisenos.
The drug was named after the Hindu god of pain and suffering, Bhagavad Gita.
Singh told The Guardian that the drug works by activating the pain receptors in the body’s nerves and releasing an opioid-like substance into the bloodstream.
This produces the same effects as morphine, which is an opioid that is a painkiller.
The opioid helps to stop the flow of blood and other bodily fluids into the brain, causing a headache, nausea, vomiting, and a loss of appetite.
The effect is similar to that of opioids, but unlike opioids, baisenzymes also act on receptors in immune cells.
Singh’s drug is currently being tested in India, and the drug’s potential for the treatment of chronic pain is being explored by researchers at the Indian Institute of Technology (IIT) in Kanpur.
He hopes to have the drug ready for the general public by next year.
The Indian government has set aside $200 million for research on bausens.
“We will start to test baisins and we hope that within five years, we will have a product available for the Indian market,” Singh said.
“The drug should be available by next April or May.
That would be great.”
He said he hoped the drug would be available in India by 2020.
The Drug Policy Alliance, a group of about 200 organizations, has pushed for more research on the bausen drug and other herbal medicines, and in March, the organization issued a press release announcing plans to work with the IMA to “research the potential of bausenos for the alleviation of pain, fever, and inflammation.”
“This research should be focused on developing a drug that is suitable for clinical use,” the statement said.
The IMA, which has the authority to regulate the Indian pharmaceutical industry and to ban any pharmaceutical company from using patented medicines in India if they do not have a patent, has already approved bauseno as a bausenic treatment.
In June, India banned the sale of the drug in India because of concerns about its potential for abuse.
Singh said he was working with the Indian government to obtain a license for bausenzymes, which would allow the drug to be sold in India.
Singh is now working with a leading Indian pharmaceutical company, Novartis, to develop a drug to treat chronic pain.
The government plans to begin trials of the bauxins next year, he said, adding that it would cost $200,000 to $250,000.
“This will be a very costly drug to develop, but this is the only way we can make it available to the Indian population,” he told The New York Times.
The IMA, which had been hesitant to approve bausenes because of fears of abuse, is now welcoming the drug as a potential treatment for chronic pain, but said it has not yet decided if it will grant a license to Novartic.
“India is a country where people have a wide range of problems, so it is important that we give people access to treatments that they can access,” said Dr. Prabhat K. Pandey, the president of the IMS, in an interview with The Times of India.
The study, published in the April issue of the journal Pain, did not include a comparison of bauxens with morphine or other painkillers.
However, Singh told the Times of Indian that the bauens had fewer side effects and had less of a potential for addiction.
Singh described the drug at the IASR as “a wonder drug,” but cautioned that there was still much work to be done before it could be widely used.
“But I am optimistic,” he added.
“I have no doubts that this is going to help people.
I don’t know what else I can do for them.”